Hereditary breast and ovarian cancer
Journal Title: Postępy Nauk Medycznych - Year 2010, Vol 23, Issue 7
Abstract
Familial breast cancer was first recognized in the Roman medical literature of 100 AD (1). The first documentation of familial clustering of breast cancer in modern times was published by Broca, who reported 10 cases of breast cancer in 4 generations of his wife’s family (2). In the middle of nineties it was proven at molecular level that substantial number of breast and ovarian cancers has hereditary monogenic etiology (3, 4). Evaluation of frequency of pedigree-clinical signs characteristic for strong aggregations of breast/ovarian cancers among consecutive cases of cancers of these organs as well as analyses of cancer incidence in monozygotic tweens indicate that about 30% of breast and ovarian cancers develop because of strong genetic predisposition (5). In other breast/ovarian cancers significance of genetic factors was underestimated. However, recently it was possible to show characteristic constitutional baground influencing development of cancer also in patients with sporadic neoplasms. Therefore now, scientists think that in almost all patients with cancer a certain genetic backgroung should be detectable although influencing cancer risk with different degree. Genetic abnormalities strongly related with cancer are called high risk changes (genes) and abnormalities influencing cancer development with lower degree are called moderate risk changes (genes). Most frequently strong genetic predisposition to breast/ovarian cancers are related to mutations in BRCA1 and BRCA2 genes and most often it apeares as syndromes of hereditary breast cancer - site specific (HBC-ss), hereditary breast-ovarian cancer (HBOC) and hereditary ovarian cancer (HOC).In family members of families with HBC-ss syndrome only breast cancers but not ovarian cancers are observed. In HBOC syndrome families with both - breast and ovarian cancers are diagnosed and in HOC syndrome only ovarian but not breast cancers are detected. Operational clinical-pedigree criteria which we use in order to diagnose “definitively” or “with high probability” the discussed syndromes are summarized in Table 1. In vast majority of cancer cases related to moderate risk genes family history is negative. HBC-ss, HBOC, HOC syndromes are clinically and molecullary heterogenous. Mutations in BRCA1 and BRCA2 genes are the most frequent cause of these syndromes.
Authors and Affiliations
Jacek Gronwald, Tomasz Byrski, Oleg Oszurek, Jolanta Szymańska-Pasternak, Bohdan Górski, Jan Lubiński, Janusz Menkiszak, Izabella Rzepka-Górska
Keywords
Related Articles
- EP ID EP53932
- DOI -
- Views 155
- Downloads 0
Nowotwory z blastycznych plazmacytoidalnych komórek dendrytycznych – opis dwóch przypadków
Artykuł zawiera opis dwóch przypadków chorych z rozpoznaniem bardzo rzadko występujących nowotworów z blastycznych plazmacytoidalnych komórek dendrytycznych (<i>blastic plasmacytoid dendritic cell neoplasms...
Evaluation of kidney function in diabetic patients undergoing percutaneous coronary interventions
<b>Aim. </b>Increasing prevalence of chronic kidney disease (CKD) is mainly due to aging process, epidemic of diabetes and late diagnosis of asymptomatic early stages of CKD. Individuals with...
Genetyka kliniczna raka piersi i jajnika
W ostatnich latach udało się wykazać u niemal wszystkich pacjentów z rakami piersi lub jajnika charakterystyczne podłoże konstytucyjne sprzyjające rozwojowi tych nowotworów. Stwierdzono, że nosicielstwo mutacji w genach...
Czynniki genetyczne i epigenetyczne w etiopatogenezie AITD: znaczenie molekularne oraz kliniczne
W rozwoju autoimmunologicznych chorób tarczycy znaczącą rolę odgrywają interakcje pomiędzy genami, czynnikami środowiskowymi a zmianami epigenetycznymi. W naszej pracy przeglądowej skupiamy się przede wszystkim na czynni...
Hormonal replacement in adrenal insufficiency – how to treat effectively and safely
Treatment of adrenal insufficiency appears to be easy: the aim is to replace hormonaldeficiency, using mainly glucocorticoids, as well as mineralocorticoids and, optionally,adrenal androgens. However, the questions occur...